Barry Jones, Ph.D. | April 08, 2019

Bioanalytical Method Development & Validation of a Trapping-Nano-Hybrid LBA/LCMS method for Clinical Studies

Recent Application of Highly Sensitive Methods for Quantitation of Biotherapeutics in Regulated Bioanalysis
In partnership with Glenmark Pharmaceuticals, this presentation highlights Nano-LC-MS considerations, such as sensitivity, robustness, speed, ease of use, and LC system volumes. It also features our platform for protein therapeutic quantitation by LC-MS, as well as a case study of Glenmark's GBR 1302, a HER2xCD3 bispecific antibody and the first clinical candidate based on Glenmark’s proprietary BEAT® platform. 

Download the presentation to learn more.

Related Services:
Bioanalytical & ADME Laboratory Services

Accelerate and enhance your discovery, preclinical and clinical programs

Assay Development for Large-Scale Clinical Studies

Bioanalytical expertise to support large-scale, international studies

Validated bioanalytical methods list

LC/MS/MS Methods, Immunoassay Biomarker Methods and LC/MS Biomarker Methods

Bioanalytical Immunoassay Services to Accelerate Biosimilar Development

Providing the tools and experience to support biosimilar studies

Read More